Latest Healthcare It News

Anteris Technologies Global Corp. has had its trading suspension lifted following a key announcement about its capital raising plans, signaling renewed market activity.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.

dorsaVi reports breakthrough RRAM sensor performance and secures a major US physical therapy deal, backed by a $5 million capital raise and new leadership appointments.

Microba Life Sciences reports robust Q1 FY26 growth in microbiome diagnostics, introduces workflow-enhancing features, and prepares for key therapeutic deal catalysts by year-end.

Global Health Limited has accelerated its MasterCare+ SaaS platform rollout, integrating AI to streamline operations and reduce staff by 10%, while reporting a 25% EBIT improvement despite a delayed R&D refund impacting cash flow.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

Alcidion Group Limited has reported a robust start to FY26, posting $8.2 million in new sales and significantly improving its operating cash flow. The company reaffirms its guidance for positive EBITDA and cash flow for the full year.

EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.

Talius Group has raised $4 million in a recent placement, expanding its subscription base and preparing to capitalize on new aged care legislation set to take effect in November 2025.

Talius Group has secured $4 million through an upsized placement, reflecting strong investor confidence in its remote care platform amid regulatory shifts in aged care funding.

Artrya Limited has secured FDA clearance for its Salix Coronary Plaque module and raised $80 million to fuel its U.S. commercial expansion, marking a pivotal step in its transition from development to revenue generation.

Archer Materials has made significant strides in quantum computing and biochip development, enhancing qubit functionality and potassium ion testing accuracy. A new partnership with IMEC aims to accelerate biochip commercialization, supported by a robust $11.6 million cash position.